UPDATE 1-Lilly's psoriatic arthritis drug succeeds in late-stage study

April 20 (Reuters) - Eli Lilly and Co said its experimental drug, ixekizumab, reduced the signs and symptoms of active psoriatic arthritis in patients more than a placebo did in a late-stage trial.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.